Invasive fungal disease (IFD)
Conditions
Interventions
Experimental group:amphotericin B colloidal dispersion
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with clinical intravenous use of amphotericin B cholesterol sulfate complex; 2. No gender limit, aged >=18 years; 3. Patients with febrile granulocyte deficiency, undefined IFD, suspected IFD, clinically diagnosed IFD, and confirmed IFD; 4. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with irregular dosage and time of amphotericin B cholesterol sulfate complex and no continuous administration for 6 days; 2. Patients with incorrect or incomplete blood collection time; 3. Pregnant and lactating patients, patients of childbearing age who refused to take effective contraceptive measures during the study period; 4. Patients who were also treated with amphotericin B in other forms during the study; 5. Patients who had been treated with amphotericin B and lipid formulates within one month prior to study initiation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effectiveness of treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of acute kidney injury;The total hospital stay;All-cause mortality;Incidence of other adverse reactions; | — |
Countries
China
Contacts
Public ContactZhang Xiaojian
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed